Pfizer Clinical Trials | NovaPharmaNews

Company details

Status: Public
HQ: New York 10017, US
Employees: 103,316
Programs: 98
Drugs: 80
Patents: 0

Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses Jun 8, 2026
Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win Jun 7, 2026

View all news & analysis →

Recent trial activity

8 updates

Latest clinical program signals indexed for Pfizer.

Trial registry

104 studies

NCT00038467
Tamoxifen

Phase 3 completed small_molecule

Breast Neoplasms

CT.gov ↗
NCT00068952
Edotecarin

Phase 3 completed small_molecule

Glioblastoma

CT.gov ↗
NCT00139698
olmesartan alone or in combination with hydrochlorothiazide

Phase 3 completed small_molecule

Essential Hypertension

CT.gov ↗
NCT00143234
Amlodipine/atorvastatin single pill

Phase 3 completed small_molecule

Hypertension

CT.gov ↗
NCT00147589
Eplerenone

Phase 3 completed small_molecule

Hypertension

CT.gov ↗
NCT00147615
Eplerenone

Phase 3 completed small_molecule

Hypertension

CT.gov ↗
NCT00150202
pegaptanib sodium

Phase 3 completed small_molecule

Macular Degeneration

CT.gov ↗
NCT00156078
pregabalin

Approved completed small_molecule

Diabetic Neuropathy, Painful

CT.gov ↗
NCT00232180
Eplerenone

Phase 3 completed small_molecule

Heart Failure

CT.gov ↗
NCT00254566
Moxifloxacin

Phase 3 completed small_molecule

Chronic Bronchitis

CT.gov ↗
NCT00257192
placebo

Phase 3 terminated small_molecule

Schizophrenia

CT.gov ↗
NCT00373113
Capecitabine

Phase 3 terminated small_molecule

Breast Neoplasms

CT.gov ↗
NCT00381095
Pregabalin

Approved terminated small_molecule

Bone Neoplasms

CT.gov ↗
NCT00389441
AG-013736

Phase 2 completed small_molecule

Thyroid Neoplasms

CT.gov ↗
NCT00407537
Amlodipine besylate/atorvastatin calcium single pill combination

Approved completed small_molecule

Hypertension

CT.gov ↗
NCT00413699
CP-690,550

Phase 3 completed small_molecule

Arthritis, Rheumatoid

CT.gov ↗
NCT00427934
Maraviroc

Phase 2 terminated small_molecule

Arthritis, Rheumatoid

CT.gov ↗
NCT00430716
Sildenafil citrate

Approved terminated small_molecule

Pulmonary Arterial Hypertension

CT.gov ↗
NCT00483548
Ziprasidone

Phase 3 completed small_molecule

Bipolar Disorder

CT.gov ↗
NCT00537238
pregabalin

Phase 3 completed small_molecule

Partial Seizures

CT.gov ↗
NCT00537329
Anidulafungin

Phase 3 completed small_molecule

Candidemia

CT.gov ↗
NCT00542009
CE-326,597 100 mg QD

Phase 2 completed small_molecule

Weight Management

CT.gov ↗
NCT00562965
inotuzumab ozogamicin

Phase 3 terminated small_molecule

Lymphoma, Follicular

CT.gov ↗
NCT00574873
Bosutinib

Phase 3 completed small_molecule

Chronic Myeloid Leukemia

CT.gov ↗
NCT00603473
gabapentin

Phase 3 completed small_molecule

Epilepsies, Partial

CT.gov ↗
NCT00631371
Bevacizumab

Phase 3 completed small_molecule

Renal Cell Carcinoma

CT.gov ↗
NCT00643734
azithromycin sustained release

Phase 3 completed small_molecule

Pneumonia

CT.gov ↗
NCT00644449
azithromycin SR (Zithromax; compound: CP-62,993)

Phase 3 completed small_molecule

Bronchitis, Chronic

CT.gov ↗
NCT00644605
sildenafil

Phase 3 completed small_molecule

Hypertension, Pulmonary

CT.gov ↗
NCT00647543
Atorvastatin

Approved completed small_molecule

Dyslipidemias

CT.gov ↗
NCT00650598
valdecoxib

Approved completed small_molecule

Pain, Postoperative

CT.gov ↗
NCT00667810
bapineuzumab

Phase 3 terminated small_molecule

Alzheimer Disease

CT.gov ↗
NCT00673049
CP 751,871 (Figitumumab)

Phase 3 terminated small_molecule

Carcinoma, Large Cell

CT.gov ↗
NCT00699374
sunitinib malate

Phase 3 terminated small_molecule

Carcinoma, Hepatocellular

CT.gov ↗
NCT00716859
Timolol

Phase 3 completed small_molecule

Glaucoma

CT.gov ↗
NCT00721409
PD 0332991

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT00732992
Sunitinib, Pemetrexed

Phase 1 completed small_molecule

Neoplasm, Malignant

CT.gov ↗
NCT00795639
Sitaxsentan

Phase 3 terminated small_molecule

Pulmonary Arterial Hypertension

CT.gov ↗
NCT00807846
Celecoxib

Approved completed small_molecule

Arthritis, Juvenile Rheumatoid

CT.gov ↗
NCT00814307
CP-690,550

Phase 3 completed small_molecule

Arthritis, Rheumatoid

CT.gov ↗
NCT00823979
UK-453,061 Dose 1

Phase 2 terminated small_molecule

HIV-1

CT.gov ↗
NCT00894374
Artesunate (Test)

Phase 1 completed small_molecule

Falciparum Malaria

CT.gov ↗
NCT00932451
PF-02341066

Phase 3 completed small_molecule

Carcinoma, Non-Small-Cell Lung

CT.gov ↗
NCT00932893
PF-02341066

Phase 3 completed small_molecule

Carcinoma, Non-Small-Cell Lung

CT.gov ↗
NCT00936065
Etanercept

Approved completed small_molecule

Moderate to Severe Psoriasis

CT.gov ↗
NCT00977015
Treatment A

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT01039688
CP-690,550

Phase 3 completed small_molecule

Arthritis, Rheumatoid

CT.gov ↗
NCT01043276
Treatment A

Phase 1 completed small_molecule

Asthma

CT.gov ↗
NCT01049217
pregabalin

Phase 3 terminated small_molecule

Neuropathy

CT.gov ↗
NCT01122498
BMP-655/ACS+Standard of care or Standard of care

Phase 1 terminated mab

Rotator Cuff Tear

CT.gov ↗
NCT01143805
Tasocitinib 10 mg oral tablet

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT01180049
temsirolimus

Approved completed small_molecule

Non-Hodgkin's Lymphoma

CT.gov ↗
NCT01186757
PF-03715455

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT01262677
pregabalin

Phase 3 completed small_molecule

Partial Seizures

CT.gov ↗
NCT01287897
PF-04236921 SC injection

Phase 2 completed small_molecule

Crohn's Disease

CT.gov ↗
NCT01321463
PH-797804

Phase 2 completed small_molecule

Pulmonary Disease, Chronic Obstructive

CT.gov ↗
NCT01337765
BEZ235 + MEK162

Phase 1 completed small_molecule

Unspecified Adult Solid Tumor, Protocol Specific

CT.gov ↗
NCT01371838
Ceftaroline

Phase 3 completed small_molecule

Community-Acquired Bacterial Pneumonia

CT.gov ↗
NCT01458574
Placebo

Phase 3 completed small_molecule

Ulcerative Colitis

CT.gov ↗
NCT01499290
CAZ-AVI

Phase 3 completed small_molecule

Complicated Intra-Abdominal Infection

CT.gov ↗
NCT01513928
Pf-04937319

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT01522807
PF-05190457

Phase 1 completed small_molecule

Diabetes Mellitus, Type 2

CT.gov ↗
NCT01599377
tofacitinib 10 mg

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT01644643
Ceftazidime - Avibactam ( CAZ-AVI)

Phase 3 completed small_molecule

Complicated Urinary Tract Infection

CT.gov ↗
NCT01726023
Ceftazidime-avibactam

Phase 3 completed small_molecule

Complicated Intra-abdominal Infection

CT.gov ↗
NCT01740427
PD-0332991

Phase 3 completed small_molecule

Breast Neoplasms

CT.gov ↗
NCT01838044
pregabalin and celecoxib

Approved terminated small_molecule

Chronic Low Back Pain With a Neuropathic Component

CT.gov ↗
NCT01877668
Tofacitinib 5 mg BID

Phase 3 completed small_molecule

Psoriatic Arthritis

CT.gov ↗
NCT01911273
PF-03446962

Phase 2 terminated small_molecule

Carcinoma, Hepatocellular

CT.gov ↗
NCT01942135
Palbociclib

Phase 3 completed small_molecule

Metastatic Breast Cancer

CT.gov ↗
NCT01975389
bococizumab (PF-04950615)

Phase 3 terminated small_molecule

Cardiovascular Disease

CT.gov ↗
NCT01989676
PF-05280014

Phase 3 completed mab

Metastatic Breast Cancer

CT.gov ↗
NCT02072824
Pregabalin Dose Level 1

Phase 3 completed small_molecule

Partial Onset Seizures

CT.gov ↗
NCT02100228
Apixaban

Approved completed small_molecule

Atrial Fibrillation

CT.gov ↗
NCT02187055
Tofacitinib with methotrexate

Approved completed small_molecule

Rhematoid Arthritis

CT.gov ↗
NCT02213263
PF-05280586

Phase 3 completed mab

Follicular Lymphoma

CT.gov ↗
NCT02222493
PF-06438179

Phase 3 completed mab

Rheumatoid Arthritis

CT.gov ↗
NCT02364999
Bevacizumab-Pfizer

Phase 3 completed small_molecule

Non-Small Cell Lung Cancer

CT.gov ↗
NCT02996500
PF-06650833

Phase 2 completed small_molecule

Rheumatoid Arthritis

CT.gov ↗
NCT03189745
MenACWY-TT

Phase 3 completed mab

Meningococcal ACWY Disease

CT.gov ↗
NCT03329092
ATM-AVI

Phase 3 completed small_molecule

Complicated Intra-abdominal Infection

CT.gov ↗
NCT03580044
ATM-AVI

Phase 3 terminated other

Serious Bacterial Infection

CT.gov ↗
NCT03642132
Chemotherapy + avelumab followed by avelumab + talazoparib

Phase 3 terminated small_molecule

Ovarian Cancer

CT.gov ↗
NCT03677596
inotuzumab ozogamicin-dose level 2

Approved completed small_molecule

Leukemia

CT.gov ↗
NCT03732807
PF-06651600 Induction Dose

Phase 3 completed small_molecule

Alopecia Areata

CT.gov ↗
NCT04165317
PF-06801591

Phase 3 active small_molecule

Non-muscle Invasive Bladder Cancer

CT.gov ↗
NCT04237792
dexmedetomidine

Approved completed small_molecule

MRI Sedation

CT.gov ↗
NCT04404283
Brentuximab vedotin

Phase 3 active small_molecule

Diffuse Large B-cell Lymphoma

CT.gov ↗
NCT04424316
RSVpreF

Phase 3 completed mab

Respiratory Tract Infection

CT.gov ↗
NCT04585815
Sasanlimab Prefilled syringe

Phase 2 terminated small_molecule

Carcinoma, Non-Small-Cell Lung

CT.gov ↗
NCT04774094
Zavicefta, Ceftazidime-Avibactam

Approved completed small_molecule

Hospital-Acquired Pneumonia

CT.gov ↗
NCT04821622
talazoparib plus enzalutamide

Phase 3 active small_molecule

Prostate Cancer

CT.gov ↗
NCT04863417
PF-07038124 or vehicle

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT04879329
disitamab vedotin

Phase 2 active small_molecule

Urothelial Carcinoma

CT.gov ↗
NCT04960202
PF-07321332

Phase 3 completed small_molecule

COVID-19

CT.gov ↗
NCT05011513
PF-07321332

Phase 3 completed small_molecule

COVID-19

CT.gov ↗
NCT05059522
Avelumab

Phase 3 active small_molecule

Advanced Malignancies

CT.gov ↗
NCT05070845
PF-06835375

Phase 2 active mab

Primary Immune Thrombocytopenia

CT.gov ↗
NCT05156398
Rimegepant

Phase 3 active small_molecule

Migraine

CT.gov ↗
NCT05540522
Quadrivalent influenza modRNA vaccine

Phase 3 completed mab

Influenza, Human

CT.gov ↗
NCT05989048
Zavegepant

Phase 3 completed small_molecule

Migraine

CT.gov ↗
NCT06102174
Placebo

Phase 1 terminated small_molecule

Respiratory Syncytial Virus Infections

CT.gov ↗
NCT06758401
Sigvotatug Vedotin

Phase 3 active small_molecule

Non-Small Cell Lung Cancer

CT.gov ↗
NCT07363694
PF-07275315 dose 1

Phase 3 active small_molecule

Moderate to Severe Chronic Obstructive Pulmonary Disease

CT.gov ↗